Oncology Institute Files 2023 Annual Report Amendment
Ticker: TOIIW · Form: 10-K/A · Filed: May 22, 2024 · CIK: 1799191
| Field | Detail |
|---|---|
| Company | Oncology Institute, Inc. (TOIIW) |
| Form Type | 10-K/A |
| Filed Date | May 22, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $11.50, $0.55 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, annual-report, healthcare
Related Tickers: TOI
TL;DR
Oncology Institute (TOI) filed its amended 2023 10-K on 5/22. Check for updates.
AI Summary
Oncology Institute, Inc. filed an amendment (No. 2) to its 2023 annual report on May 22, 2024. The company, formerly known as DFP Healthcare Acquisitions Corp., is headquartered in Cerritos, CA. This filing relates to the fiscal year ended December 31, 2023.
Why It Matters
This amendment provides updated information for the fiscal year 2023, which could contain material changes affecting investors' understanding of the company's financial health and operations.
Risk Assessment
Risk Level: low — This is an amendment to an annual report, typically for corrections or updates, not a new filing indicating significant new risks.
Key Numbers
- 001-39248 — SEC File Number (Identifies the company's filings with the SEC.)
- 84-3562323 — IRS Number (Company's Employer Identification Number.)
Key Players & Entities
- Oncology Institute, Inc. (company) — Registrant
- DFP HEALTHCARE ACQUISITIONS CORP. (company) — Former Company Name
- 2023-12-31 (date) — Fiscal Year End
- 20240522 (date) — Filing Date
- 18000 STUDEBAKER RD SUITE 800 CERRITOS CA 90703 (address) — Business Address
FAQ
What specific information is being amended in this 10-K/A filing?
The filing is an amendment (No. 2) to the annual report for the fiscal year ended December 31, 2023, but the specific details of the amendments are not provided in this header information.
When was the company formerly known as DFP HEALTHCARE ACQUISITIONS CORP.?
The company changed its name from DFP HEALTHCARE ACQUISITIONS CORP. on January 8, 2020.
What is the primary business address of Oncology Institute, Inc.?
The business address is 18000 STUDEBAKER RD, SUITE 800, CERRITOS, CA 90703.
What is the SEC file number for Oncology Institute, Inc.?
The SEC file number is 001-39248.
On what date was this amendment filed?
This amendment was filed on May 22, 2024.
Filing Stats: 1,262 words · 5 min read · ~4 pages · Grade level 12.7 · Accepted 2024-05-22 16:05:28
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share TOI The Nasdaq St
- $11.50 — mon stock, each at an exercise price of $11.50 per share TOIIW The Nasdaq Stock Mark
- $0.55 — gistrant, based on the closing price of $0.55 per shares of the Registrant's common s
Filing Documents
- toi_10ka.htm (10-K/A) — 53KB
- ex31x1.htm (EX-31.1) — 8KB
- ex31x2.htm (EX-31.2) — 7KB
- 0001553350-24-000039.txt ( ) — 333KB
- toi-20231231.xsd (EX-101.SCH) — 4KB
- toi-20231231_def.xml (EX-101.DEF) — 28KB
- toi-20231231_lab.xml (EX-101.LAB) — 39KB
- toi-20231231_pre.xml (EX-101.PRE) — 27KB
- toi_10ka_htm.xml (XML) — 9KB
Exhibits, Financial Statement Schedules
Item 15. Exhibits, Financial Statement Schedules. (a) Documents filed as part of the Annual Report on Form 10-K, as amended by this Amendment No. 2 (1) Financial Statements: See Index to Consolidated Financial (2) Financial Statement Schedules: No financial statement schedules are included in the Original 10-K or this Amendment No. 2 as such schedules are not required or the information that would be included in such schedules is not material or is otherwise furnished. (b) Exhibits: See Index to Exhibits below. Incorporated by Reference Filed or Furnished Herewith Exhibit Number Description Form File Number Exhibit Filing Date 31.1 Certification Pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934 of the Principal Executive Officer. X 31.2 Certification Pursuant to Rule 13a-14(a) under Securities Exchange Act of 1934 of the Principal Financial Officer. X 104 Cover Page Interactive Data File - (formatted as Inline XBRL and contained in Exhibit 101) 4
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Amendment No. 2 to the Annual Report on Form 10-K/A to be signed on its behalf by the undersigned hereunto duly authorized, on May 22, 2024. THE ONCOLOGY INSTITUTE, INC. By: /s/ Mihir Shah Mihir Shah Chief Financial Officer (Principal Financial Officer and Duly Authorized Officer) Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons in the capacities held on the dates indicated. Signature Title Date * Daniel Virnich Chief Executive Officer (Principal Executive Officer) May 22, 2024 /s/ Mihir Shah Mihir Shah Chief Financial Officer (Principal Financial and Accounting Officer) May 22, 2024 * Richard Barasch Director May 22, 2024 * Karen Johnson Director May 22, 2024 * Mohit Kaushal Director May 22, 2024 * Gabriel Ling Director May 22, 2024 * Anne McGeorge Director May 22, 2024 * Maeve O'Meara Director May 22, 2024 * Mark Pacala Director May 22, 2024 * Brad Hively Director May 22, 2024 ___________ * By Mihir Shah, as attorney-in-fact.